Silence Therapeutics prices upsized offering at $13.50 per ADS

Silence Therapeutics has priced its upsized public offering of 150 million American Depositary Shares (ADS) at $13.50 per ADS. The offering, which was increased from an initial proposal, reflects investor interest in the company’s pipeline and strategic direction. The ADSs are being offered under a shelf registration statement previously filed with the U.S. Securities and Exchange Commission (SEC). The transaction is expected to generate significant capital for the company, which may be used to advance its research and development initiatives, strengthen its balance sheet, or pursue strategic opportunities. The offering is not a guarantee of future performance or financial success, and investors are advised to conduct due diligence and consider market risks. The company has not disclosed specific allocation plans for the proceeds at this time. The offering is subject to customary closing conditions and is expected to settle in the coming weeks.